Analyst Ratings For Immune Design (NASDAQ:IMDZ)
Today, Jefferies Group reiterated its Buy rating on Immune Design (NASDAQ:IMDZ) with a price target of $8.00.
Some recent analyst ratings include
- 3/15/2018-Jefferies Group Reiterated Rating of Buy.
- 12/11/2017-Cowen Reiterated Rating of Buy.
- 10/17/2017-Wells Fargo & Co was Downgraded by analysts at Wells Fargo & Co from a “Outperform ” rating to a ” Market Perform” rating. They now have a $10.00 price target on the stock, up previously from $29.00 .
- 9/14/2017-Royal Bank of Canada initiated coverage with a Outperform rating.
- 6/10/2016-Leerink Swann Reiterated Rating of Buy.
Recent Insider Trading Activity For Immune Design (NASDAQ:IMDZ)
Immune Design (NASDAQ:IMDZ) has insider ownership of 20.70% and institutional ownership of 53.86%.
- On 1/8/2018 Leo Guthart, Major Shareholder, bought 20,000 with an average share price of $3.90 per share and the total transaction amounting to $78,000.00.
- On 1/5/2018 Carlos V Paya, CEO, sold 7,970 with an average share price of $4.17 per share and the total transaction amounting to $33,234.90.
- On 1/5/2018 Meulen Jan Henrik Ter, Insider, sold 1,986 with an average share price of $4.17 per share and the total transaction amounting to $8,281.62.
- On 1/5/2018 Stephen R Brady, EVP, sold 3,328 with an average share price of $4.17 per share and the total transaction amounting to $13,877.76.
- On 1/4/2018 Sergey Yurasov, VP, sold 675 with an average share price of $4.17 per share and the total transaction amounting to $2,814.75.
- On 11/2/2017 Lewis W Coleman, Director, bought 50,000 with an average share price of $4.50 per share and the total transaction amounting to $225,000.00.
- On 10/30/2017 Franklin M Berger, Director, bought 25,000 with an average share price of $4.58 per share and the total transaction amounting to $114,500.00.
Recent Trading Activity for Immune Design (NASDAQ:IMDZ)
Shares of Immune Design closed the previous trading session at with shares trading hands.